Baers Justin H, Adekanye Joel, Hazlewood Glen, Davies Jan M, Caird Jeff K, Wilton Stephen B
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada.
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 2TP, Canada.
Rev Cardiovasc Med. 2022 Oct 18;23(10):353. doi: 10.31083/j.rcm2310353. eCollection 2022 Oct.
Atrial Fibrillation (AF) is a major cause of stroke. Oral anticoagulation can reduce the risk of AF-associated stroke by 65% but it remains underused. Stroke prevention therapy in patients with AF has been considered a good target for shared decision making with patient decision aids as it is a long-term, preference-sensitive decision with known risk-benefit trade-offs. The aim of this systematic review was to summarize published literature on the effectiveness of patient decision aids on the choice of and adherence to stroke prevention therapy in individuals with AF.
We conducted a structured literature search for prospective studies evaluating decision aids for AF stroke prevention therapy in adult patients with nonvalvular AF. We included studies that compared those exposed to a decision aid with a control condition for outcomes including choice of therapy, adherence, decisional conflict and patient knowledge. Quantitative meta-analysis was not feasible due to excessive between-study heterogeneity.
Eight studies met inclusion and exclusion criteria. Six studies were randomized clinical trials and two were pre-post comparisons. Of the 8 studies, each evaluated a different decision aid, with only three including all contemporary oral anticoagulant drugs. All decision aids improved AF knowledge compared to baseline or control and decision aids reduced decisional conflict in four of six studies. However, there were inconsistent effects of the studied decision aids on initiation of oral anticoagulation. Adherence to initial stroke prevention therapy choice appeared to benefit from decision aid use in 2 studies that addressed this issue.
Decision aids for stroke prevention increased AF patients' knowledge and decisional confidence but had variable impacts on choice of and adherence to stroke prevention therapy. The results highlight the need for well-designed decision aids that present patients with all contemporary therapeutic options.
心房颤动(AF)是中风的主要原因。口服抗凝药可将与AF相关的中风风险降低65%,但仍未得到充分利用。AF患者的中风预防治疗被认为是与患者决策辅助工具共同决策的良好目标,因为这是一个长期的、偏好敏感的决策,且已知风险效益权衡。本系统评价的目的是总结已发表的关于患者决策辅助工具对AF患者中风预防治疗选择和依从性有效性的文献。
我们对评估非瓣膜性AF成年患者AF中风预防治疗决策辅助工具的前瞻性研究进行了结构化文献检索。我们纳入了将接受决策辅助工具的患者与对照条件进行比较的研究,以评估包括治疗选择、依从性、决策冲突和患者知识等结果。由于研究间异质性过大,无法进行定量荟萃分析。
八项研究符合纳入和排除标准。六项研究为随机临床试验,两项为前后比较。在这8项研究中,每项研究评估了一种不同的决策辅助工具,只有三项研究涵盖了所有当代口服抗凝药物。与基线或对照相比,所有决策辅助工具都提高了AF知识,并且在六项研究中的四项中,决策辅助工具减少了决策冲突。然而,所研究的决策辅助工具对口服抗凝治疗起始的影响并不一致。在两项涉及此问题的研究中,使用决策辅助工具似乎有利于坚持最初的中风预防治疗选择。
中风预防决策辅助工具增加了AF患者的知识和决策信心,但对中风预防治疗的选择和依从性有不同影响。结果强调需要设计良好的决策辅助工具,为患者提供所有当代治疗选择。